BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care ... ( LYNBROOK N.Y. March 10 /- BioSpecific...)

BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference

Date:3/10/2009

LYNBROOK, N.Y., March 10 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming Cowen and Company 29th Annual Health Care Conference on Tuesday, March 17, 2009, at 9:30am ET at the Boston Marriott Copley Place in Boston, MA. A live webcast of the presentation can be accessed at www.biospecifics.com ("Future Company Presentation March 17, 2009"). The presentation will be archived for 90 days.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for three clinical indications: Dupuytren's disease; Peyronie's disease; and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. has filed a Biologic License Application with the U.S. Food and Drug Administration to market injectable collagenase (XIAFLEX(TM)) in the U.S. for the treatment of Dupuytren's disease, while Pfizer, Inc. is responsible for commercialization of XIAFLEX(TM) in Europe and other territories.

SOURCE BioSpecifics Technologies Corp.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1
Related medicine technology :

1. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
2. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
3. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
4. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
5. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
6. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
7. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
8. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
9. Senesco Technologies Initiates Preclinical Studies for Cancer Target
10. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
11. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine

Post Your Comments:

BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care ...( LYNBROOK N.Y. March 10 /- BioSpecific...),Health